SCHEMBL2279827

SCHEMBL2279827

CC(=O)c1c(O)cc(C)n(Cc2ccccc2)c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.59
TSHR P16473 3/20 0.59
LMNA P02545 3/20 0.59
NOTUM Q6P988 1/20 0.51
ALDH1A1 P00352 5/20 0.48
KDM4E B2RXH2 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPK1 P28482 1/20 0.47
SRC P12931 1/20 0.46
KMT2A Q03164 3/20 0.45
RAB9A P51151 2/20 0.44
S1PR2 O95136 1/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 2/20 0.43
HTT P42858 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13678555 0.82 NOTUM (0.53) SMN1; SMN2TSHRLMNANOTUMALDH1A1
SCHEMBL13678559 0.79 ALDH1A1 (0.50) SMN1; SMN2TSHRLMNANOTUMALDH1A1
SCHEMBL4382351 0.79 ALDH1A1 (0.50) SMN1; SMN2TSHRLMNANOTUMALDH1A1
SCHEMBL11609712 0.79 NOTUM (0.57) SMN1; SMN2TSHRLMNANOTUMALDH1A1
SCHEMBL7221090 0.79 L3MBTL1 (0.48) TSHRLMNAKDM4EL3MBTL1KMT2A
SCHEMBL4473176 0.78 KMT2A (0.54) SMN1; SMN2TSHRLMNANOTUMALDH1A1
SCHEMBL2285212 0.75 L3MBTL1 (0.74) SMN1; SMN2TSHRLMNANOTUMALDH1A1
SCHEMBL2279647 0.74 L3MBTL1 (0.46) SMN1; SMN2TSHRLMNAALDH1A1KDM4E
SCHEMBL2282860 0.72 KDM4E (0.47) SMN1; SMN2TSHRALDH1A1KDM4EL3MBTL1
SCHEMBL13401691 0.72 SMN1; SMN2 (0.56) SMN1; SMN2TSHRLMNANOTUMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 SMN1; SMN2 3766/4885TSHR 4777/4885LMNA 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.